Security record · archived quarter
BPMC
Blueprint Medicines Corporation · Healthcare · Biotechnology
12Tracked holders
n/aΔ holders
13.51MShares held
$1.46BReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 5.87M | n/a | $633.03M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 2 | Wellington Management ✦ | 3.24M | n/a | $348.73M | 0.1% | n/c | 1 | SEC ↗ ×7 |
| 3 | Geode Capital Management ✦ (passive) | 1.46M | n/a | $157.33M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Millennium Management ✦ | 627.63K | n/a | $67.65M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | Norges Bank ✦ (passive) | 592.13K | n/a | $63.82M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Point72 Asset Management ✦ | 501.58K | n/a | $54.06M | 0.2% | n/c | 1 | SEC ↗ |
| 7 | Marshall Wace ✦ | 351.76K | n/a | $37.91M | 0.1% | n/c | 1 | SEC ↗ |
| 8 | Fisher Asset Management ✦ | 336.17K | n/a | $36.23M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 302.63K | n/a | $32.62M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Renaissance Technologies ✦ | 110.40K | n/a | $11.90M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 78.10K | n/a | $8.42M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 12 | Citadel Advisors ✦ | 39.21K | n/a | $4.23M | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 2 holders, 301 shares, $38,583 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API